Αποτελέσματα Αναζήτησης
DIAGNODE-3 stands as the only ongoing Phase 3 trial worldwide for a disease-modifying therapy in Type 1 Diabetes, placing Diamyd Medical at the forefront of innovative treatments.
- Diabetes
Type 1 diabetes and LADA are autoimmune forms of diabetes,...
- Products
The Antigen-specific intralymphatic immunotherapy Diamyd ®....
- Clinical Trials
A Phase II Open Label Study to evaluate the safety and...
- The Company
DIAGNODE-3 stands as the only ongoing Phase 3 trial...
- Board & Management
Independent of the Company, major owner. Founder of...
- Scientific Advisory Board
Diamyd Medical Scientific and Medical Advisory Board....
- Scientific Publications
Intralymphatic GAD-Alum (Diamyd ®) Improves Glycemic Control...
- Events & Mediawatch
Events & Mediawatch - Diamyd Medical - Developing precision...
- Diabetes
14 Νοε 2024 · DIAGNODE-3 stands as the only ongoing Phase 3 trial worldwide for a disease-modifying therapy in Type 1 Diabetes, placing Diamyd Medical at the forefront of innovative treatments. Diamyd Medical develops precision medicine therapies for the prevention and treatment of autoimmune diabetes.
Diamyd is under development for the treatment of LADA (latent autoimmune diabetes in adults), prevention and treatment of type 1 diabetes. It is an antigen-specific immunomodulatory therapeutic which is administered through subcutaneous, intra-inguinal and intralymphatic route.
6 Ιουν 2022 · Autoantigen therapy with GAD-alum (Diamyd) given in 3 intralymphatic injections with oral vitamin D has shown promising results in persons with T1D carrying the human leukocyte antigen (HLA) DR3-DQ2 haplotype in the phase 2b trial DIAGNODE-2.
31 Ιουλ 2024 · Patients recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype will receive oral vitamin D (cholecalciferol 2000 IU) supplementation with either 3 injections of Diamyd® or placebo to evaluate safety and efficacy of Diamyd in preserving endogenous beta cell function and influencing glycemic parameters.
1 Νοε 2008 · Diamyd Medical AB is developing Diamyd (GAD-65), an alum formulation of a full-length recombinant human glutamic acid decarboxylase 65 for subcutaneous injection, for the potential prevention and...
Diamyd, the company's lead compound, is an alum formulation of full-length recombinant human GAD65 (rhGAD65) [744043]. At the time of publication, phase II clinical trials had been completed in...
